logo
4576

D.Western Therapeutics Institute Inc

¥118.00¥0.00  (0%)
EPS
-33.82
Market cap
¥4.48B
Start your journey to financial independence
Snowball will help you to track your portfolio, plan deposits to your brokerage account and increase passive income
Start
Price history
Mar 14, 24 - Mar 14, 25-¥6.00 (4.84%)
2502502002001501501001005050Apr '24Apr '24May '24May '24Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Sep '24Sep '24Oct '24Oct '24Nov '24Nov '24Dec '24Dec '2420252025Feb '25Feb '25Mar '25Mar '25min: ¥61max: ¥235
Estimate
EPS
-33.82
Growth
Revenue, YoY
21.49%
Net income, YoY
-33.12%
About the company
Ticker
4576
ISIN
JP3548740004
Country
Japan
Sector (GICS)
Healthcare
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.

It looks as if this company does not pay dividends

This place looks empty

Comments

Join our community 🤝

Exchange you thoughts and ideas with other investors
Sign up for free